| abstract |
Substituted 2,3-diaminopyridine derivatives with HDAC inhibitory activity, a pharmaceutical composition that comprises them and their use in the treatment of CNS diseases. Claim 1: A compound characterized in that it responds to formula (1); or a pharmaceutical acceptable salt thereof, wherein: Ring A is phenyl or thiophenyl; X is (CRᵃRᵇ) ₜ, O or NR⁵; q is 0, 1 or 2; t is 1, 2, or 3; R¹ is phenyl or heteroaryl, each of which is optionally substituted with 1 to 3 groups selected from Rᶜ; R² is halo, C₁₋₄alkyl, C₁₋₄alkoxy and OH; R³ is hydrogen or halo; R⁴ is halo when ring A is phenyl and R⁴ is hydrogen when ring A is thiophenyl; R⁵ is hydrogen, C₁₋₄alkyl-OC₁₋₄alkyl; Rᵃ and Rᵇ are each independently hydrogen, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, or halo; and Rᶜ is halo, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy, C₁₋₄alkyl-OC₁₋₄alkyl, C₁₋₄alkyl-NHC₁₋₄alkyl, C₁₋₄alkyl-N (C₁₋₄alkyl) ₂, - C₁₋₄alkylheteroaryl or -C₁₋₄alkylheterocyclyl, wherein said heteroaryl and heterocyclyl are each optionally and independently substituted with 1 to 3 groups selected from C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy and halo. |